GCG and heart failure: Our network meta-analyses demonstrated that, in terms of heart failure risk, SGLT-2 inhibitors were the most favorable option among all classes of anti-diabetic medications; DDP-4 inhibitors and GLP-1 agonists seemed inferior to SGLT-2 inhibitors and metformin.